August 28, 2026
https://www.brighteon.com/67ead022-3af1-4e1b-bfa5-4bb21923af36
August 28, 2026
“Voyager Technologies reported Q2 revenue of $52.7 million, up 51% sequentially, and a loss of $0.70 per share, beating analyst estimates. The company posted record bookings of $113 million and expanded its backlog to $335.5 million. TD Securities analyst Gautam… Continue Reading…
August 28, 2026
“International Business Machines (NYSE: IBM) trades at about $224 as of this writing, roughly 33% below its 52-week high of $332.46. The slide has pushed the technology veteran’s dividend yield to about 3% — a level that tends to attract income… Continue Reading…
August 28, 2026
“…One notable example of Druckenmiller’s risk-taking is his investments in clinical-stage biotech stocks. In the first quarter of 2026, his Duquesne Family Office initiated a new stake in Revolution Medicines (NASDAQ: RVMD) worth $30.7 million at the end of Q1… Over the last… Continue Reading…
August 27, 2026
“The semiconductor sector, as summarized by the iShares Semiconductor ETF (NASDAQ: SOXX), had a rough go of it in July. The exchange-traded fund plunged a stunning 23% from its highs in just one month, with many of the ETF’s components down by much more.… Continue Reading…
August 27, 2026
“…The company has seen its profit soar during the past few quarters as hyperscalers pay premium prices for its chips. But the market has sold off Micron along with other semiconductor stocks since late June due to a mix of… Continue Reading…
August 25, 2026
https://www.brighteon.com/56009d10-e33a-4f60-9209-fdb744f61c56 Click link above to watch video.
August 25, 2026
“Japan’s Finance Ministry said it conducted a coordinated yen-buying intervention with the U.S. Treasury on Friday. Japan said it “will not hesitate to conduct further coordinated interventions in the future” and remains in close communication with the U.S. Treasury. U.S.… Continue Reading…
August 25, 2026
“The Massachusetts-based biotechnology company announced the favorable outcome following a meeting of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. The panel voted 10-3 that the results from a key clinical study of the company’s therapy, known as RP1,… Continue Reading…
Recent Comments